{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:20:45Z","timestamp":1788895245299,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["AIRC IG 29261"],"award-info":[{"award-number":["AIRC IG 29261"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["AIRC IG 22805"],"award-info":[{"award-number":["AIRC IG 22805"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["AIRC IG 22100"],"award-info":[{"award-number":["AIRC IG 22100"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Osteosarcoma (OS) is a highly aggressive bone malignancy primarily affecting children and adolescents, with limited therapeutic options. The transcription factor ZEB1, a key regulator of epithelial-mesenchymal transition (EMT), promotes cancer stemness and tumor progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We investigated ZEB1 role in OS using genetic knockout and silencing in murine and patient-derived cellular OS models. Using in vitro functional assays, we assessed the effect of ZEB1 down-modulation on stemness (sarcosphere formation), anchorage-independent growth, chemotherapy sensitivity, and osteoblastic differentiation (osteogenic markers and matrix mineralization), while gene expression profiling provided hints on ZEB1 regulation of tumor cell transcriptional program. In vivo studies evaluated tumor growth and lung metastasis in ZEB1-deficient models, while ZEB1 restoration experiments mechanistically proved its role in OS aggressiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ZEB1 loss in OS mouse models markedly reduced stemness-associated gene expression and functional sarcosphere formation, impaired anchorage-independent growth, and increased sensitivity to chemotherapy. Furthermore, ZEB1 inhibition restored osteoblastic differentiation capacity, evidenced by upregulation of osteogenic markers and matrix mineralization.<\/jats:p>\n                    <jats:p>In vivo, ZEB1 deletion in mouse OS cells significantly hindered tumor growth and lung metastasis, accompanied by increased tumor differentiation and decreased infiltration of pro-tumoral macrophages. Gene expression profiling revealed suppression of oncogenic pathways and inflammatory mediators upon ZEB1 loss, while restoration of ZEB1 rescued OS aggressive phenotype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, our findings position ZEB1 as a critical driver of OS aggressiveness by regulating stemness, cellular differentiation, oncogenic signaling, and immune infiltration, and highlight differentiation-based therapeutic strategies as a promising avenue for osteosarcoma treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03757-9","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T03:45:10Z","timestamp":1781495110000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["ZEB1 integrates stemness, differentiation blockade and immune suppression to orchestrate osteosarcoma aggressiveness"],"prefix":"10.1186","volume":"45","author":[{"given":"Anna","family":"Zaccaria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Cascini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Botti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Pernici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Cancila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Armiraglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonina","family":"Parafioriti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Meazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Sangaletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Tripodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Scotlandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario P.","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Lecis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Chiodoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"issue":"6","key":"3757_CR1","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/jbmr.1578","volume":"27","author":"N Dani","year":"2012","unstructured":"Dani N, Olivero M, Mareschi K, van Duist MM, Miretti S, Cuvertino S, et al. The MET oncogene transforms human primary bone-derived cells into osteosarcomas by targeting committed osteo-progenitors. J Bone Min Res. 2012;27(6):1322\u201334.","journal-title":"J Bone Min Res"},{"key":"3757_CR2","doi-asserted-by":"crossref","unstructured":"Chiappetta C, Della Rocca C, Di Cristofano C. Whole-Exome Analysis and Osteosarcoma: A Game Still Open. Int J Mol Sci. 2024;25(24).","DOI":"10.3390\/ijms252413657"},{"issue":"1","key":"3757_CR3","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41467-020-14646-w","volume":"11","author":"CC Wu","year":"2020","unstructured":"Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, et al. Immuno-genomic landscape of osteosarcoma. Nat Commun. 2020;11(1):1008.","journal-title":"Nat Commun"},{"key":"3757_CR4","doi-asserted-by":"publisher","first-page":"538152","DOI":"10.1155\/2013\/538152","volume":"2013","author":"C Errani","year":"2013","unstructured":"Errani C, Traina F, Perna F, Calamelli C, Faldini C. Current concepts in the biopsy of musculoskeletal tumors. ScientificWorldJournal. 2013;2013:538152.","journal-title":"ScientificWorldJournal"},{"issue":"8","key":"3757_CR5","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nrendo.2017.16","volume":"13","author":"DM Gianferante","year":"2017","unstructured":"Gianferante DM, Mirabello L, Savage SA. Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy. Nat Rev Endocrinol. 2017;13(8):480\u201391.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"3757_CR6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1200\/JCO.2017.75.1743","volume":"36","author":"JS Whelan","year":"2018","unstructured":"Whelan JS, Davis LE. Osteosarcoma, Chondrosarcoma, and Chordoma. J Clin Oncol. 2018;36(2):188\u201393.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3757_CR7","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/cncr.24121","volume":"115","author":"L Mirabello","year":"2009","unstructured":"Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115(7):1531\u201343.","journal-title":"Cancer"},{"issue":"2","key":"3757_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/cancers5020591","volume":"5","author":"K Ando","year":"2013","unstructured":"Ando K, Heymann MF, Stresing V, Mori K, Redini F, Heymann D. Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel). 2013;5(2):591\u2013616.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"3757_CR9","first-page":"21","volume":"166","author":"MA Nieto","year":"2016","unstructured":"Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 2016 Cell. 2016;166(1):21\u201345.","journal-title":"Emt: 2016 Cell"},{"issue":"3","key":"3757_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","volume":"29","author":"I Pastushenko","year":"2019","unstructured":"Pastushenko I, Blanpain C. EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol. 2019;29(3):212\u201326.","journal-title":"Trends Cell Biol"},{"issue":"17","key":"3757_CR11","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1158\/0008-5472.CAN-17-0032","volume":"77","author":"G Sannino","year":"2017","unstructured":"Sannino G, Marchetto A, Kirchner T, Grunewald TGP. Epithelial-to-Mesenchymal and Mesenchymal-to-Epithelial Transition in Mesenchymal Tumors: A Paradox in Sarcomas? Cancer Res. 2017;77(17):4556\u201361.","journal-title":"Cancer Res"},{"issue":"7","key":"3757_CR12","first-page":"897","volume":"1","author":"E Sanchez-Tillo","year":"2011","unstructured":"Sanchez-Tillo E, Siles L, de Barrios O, Cuatrecasas M, Vaquero EC, Castells A, et al. Expanding roles of ZEB factors in tumorigenesis and tumor progression. Am J Cancer Res. 2011;1(7):897\u2013912.","journal-title":"Am J Cancer Res"},{"key":"3757_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fmolb.2020.00036","volume":"7","author":"S Drapela","year":"2020","unstructured":"Drapela S, Bouchal J, Jolly MK, Culig Z, Soucek K. ZEB1: A Critical Regulator of Cell Plasticity, DNA Damage Response, and Therapy Resistance. Front Mol Biosci. 2020;7:36.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"3757_CR14","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1038\/s41467-022-29723-5","volume":"13","author":"N Mohammadi Ghahhari","year":"2022","unstructured":"Mohammadi Ghahhari N, Sznurkowska MK, Hulo N, Bernasconi L, Aceto N, Picard D. Cooperative interaction between ERalpha and the EMT-inducer ZEB1 reprograms breast cancer cells for bone metastasis. Nat Commun. 2022;13(1):2104.","journal-title":"Nat Commun"},{"key":"3757_CR15","doi-asserted-by":"crossref","unstructured":"Kitz J, Lefebvre C, Carlos J, Lowes LE, Allan AL. Reduced Zeb1 Expression in Prostate Cancer Cells Leads to an Aggressive Partial-EMT Phenotype Associated with Altered Global Methylation Patterns. Int J Mol Sci. 2021;22(23).","DOI":"10.3390\/ijms222312840"},{"issue":"8","key":"3757_CR16","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/jso.23012","volume":"105","author":"A Shen","year":"2012","unstructured":"Shen A, Zhang Y, Yang H, Xu R, Huang G. Overexpression of ZEB1 relates to metastasis and invasion in osteosarcoma. J Surg Oncol. 2012;105(8):830\u20134.","journal-title":"J Surg Oncol"},{"issue":"2","key":"3757_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.5659","volume":"254","author":"M Ruh","year":"2021","unstructured":"Ruh M, Stemmler MP, Frisch I, Fuchs K, van Roey R, Kleemann J, et al. The EMT transcription factor ZEB1 blocks osteoblastic differentiation in bone development and osteosarcoma. J Pathol. 2021;254(2):199\u2013211.","journal-title":"J Pathol"},{"issue":"17","key":"3757_CR18","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.1158\/1078-0432.CCR-16-3186","volume":"23","author":"C Ratti","year":"2017","unstructured":"Ratti C, Botti L, Cancila V, Galvan S, Torselli I, Garofalo C, et al. Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors. Clin Cancer Res. 2017;23(17):5149\u201361.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3757_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13046-025-03440-5","volume":"44","author":"MC Manara","year":"2025","unstructured":"Manara MC, Bruzzese F, Formentini L, Landuzzi L, Pazzaglia L, Laginestra MA, et al. Genomic profiling of a collection of patient-derived xenografts and cell lines identified ixabepilone as an active drug against chemo-resistant osteosarcoma. J Exp Clin Cancer Res. 2025;44(1):195.","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"3757_CR20","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281\u2013308.","journal-title":"Nat Protoc"},{"key":"3757_CR21","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0076-6879(02)46074-0","volume":"346","author":"M De Palma","year":"2002","unstructured":"De Palma M, Naldini L. Transduction of a gene expression cassette using advanced generation lentiviral vectors. Methods Enzymol. 2002;346:514\u201329.","journal-title":"Methods Enzymol"},{"key":"3757_CR22","doi-asserted-by":"crossref","unstructured":"Giacomini I, Cortini M, Tinazzi M, Baldini N, Cocetta V, Ragazzi E et al. Contribution of Mitochondrial Activity to Doxorubicin-Resistance in Osteosarcoma Cells. Cancers (Basel). 2023;15(5).","DOI":"10.3390\/cancers15051370"},{"key":"3757_CR23","doi-asserted-by":"crossref","unstructured":"Perez G, Lopez-Moncada F, Indo S, Torres MJ, Castellon EA, Contreras HR. Knockdown of ZEB1 reverses cancer stem cell properties in prostate cancer cells. Oncol Rep. 2021;45(5).","DOI":"10.3892\/or.2021.8009"},{"issue":"12","key":"3757_CR24","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/ncb1998","volume":"11","author":"U Wellner","year":"2009","unstructured":"Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009;11(12):1487\u201395.","journal-title":"Nat Cell Biol"},{"key":"3757_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.bone.2014.02.003","volume":"62","author":"AJ Mutsaers","year":"2014","unstructured":"Mutsaers AJ, Walkley CR. Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? Bone. 2014;62:56\u201363.","journal-title":"Bone"},{"key":"3757_CR26","doi-asserted-by":"publisher","first-page":"325238","DOI":"10.1155\/2011\/325238","volume":"2011","author":"ER Wagner","year":"2011","unstructured":"Wagner ER, Luther G, Zhu G, Luo Q, Shi Q, Kim SH, et al. Defective osteogenic differentiation in the development of osteosarcoma. Sarcoma. 2011;2011:325238.","journal-title":"Sarcoma"},{"issue":"1","key":"3757_CR27","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.yexcr.2013.10.013","volume":"320","author":"B Tu","year":"2014","unstructured":"Tu B, Peng ZX, Fan QM, Du L, Yan W, Tang TT. Osteosarcoma cells promote the production of pro-tumor cytokines in mesenchymal stem cells by inhibiting their osteogenic differentiation through the TGF-beta\/Smad2\/3 pathway. Exp Cell Res. 2014;320(1):164\u201373.","journal-title":"Exp Cell Res"},{"issue":"8","key":"3757_CR28","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1111\/cas.14504","volume":"111","author":"Y Arima","year":"2020","unstructured":"Arima Y, Nobusue H, Saya H. Targeting of cancer stem cells by differentiation therapy. Cancer Sci. 2020;111(8):2689\u201395.","journal-title":"Cancer Sci"},{"issue":"1","key":"3757_CR29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13046-023-02731-z","volume":"42","author":"C Cascini","year":"2023","unstructured":"Cascini C, Ratti C, Botti L, Parma B, Cancila V, Salvaggio A, et al. Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma. J Exp Clin Cancer Res. 2023;42(1):154.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3757_CR30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/0008-5472.CAN-17-2476","volume":"78","author":"J Caramel","year":"2018","unstructured":"Caramel J, Ligier M, Puisieux A. Pleiotropic Roles for ZEB1 in Cancer. Cancer Res. 2018;78(1):30\u20135.","journal-title":"Cancer Res"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03757-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03757-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03757-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T23:33:15Z","timestamp":1787268795000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03757-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3757"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03757-9","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were approved by the Institutional Ethics Committee for Animal Use and by the Italian Ministry of Health (authorization numbers 187\/2019-PR and 401\/2022-PR to Claudia Chiodoni) and were performed following the 3Rs (Reduction, Refinement and Replacement) recommendations.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"183"}}